Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory, randomized, double-blind, placebo-controlled evaluation of efficacy, tolerability, and safety of intravesical instillation of GRT6010 compared to placebo in subjects with bladder pain syndrome [Eksploracyjne badanie kliniczne z randomizacją, prowadzone metodą podwójnie ślepej próby, z grupą kontrolną placebo, w celu oceny skuteczności, tolerancji i bezpieczeństwa preparatu GRT6010 podawanego dopęcherzowo, w porównaniu z placebo u pacjentów z zespołem bolesnego pęcherza]

Trial Profile

Exploratory, randomized, double-blind, placebo-controlled evaluation of efficacy, tolerability, and safety of intravesical instillation of GRT6010 compared to placebo in subjects with bladder pain syndrome [Eksploracyjne badanie kliniczne z randomizacją, prowadzone metodą podwójnie ślepej próby, z grupą kontrolną placebo, w celu oceny skuteczności, tolerancji i bezpieczeństwa preparatu GRT6010 podawanego dopęcherzowo, w porównaniu z placebo u pacjentów z zespołem bolesnego pęcherza]

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs GRT 6010 (Primary)
  • Indications Interstitial cystitis
  • Focus Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 05 Sep 2018 Status changed from recruiting to completed.
    • 15 May 2018 This study has been completed in Germany (End date: 2018-05-02)
    • 05 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top